2024
Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease
Armillei M, Lomakin I, Del Rosso J, Grada A, Bunick C. Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease. Antibiotics 2024, 13: 270. PMID: 38534705, PMCID: PMC10967556, DOI: 10.3390/antibiotics13030270.Peer-Reviewed Original ResearchSoft tissue infectionsTetracycline class antibioticsTreatment of dermatological diseasesMechanism of protein synthesis inhibitionClindamycin useStaphylococcal infectionsTissue infectionsClinical presentationAnti-inflammatory propertiesHidradenitis suppurativaEffective antibioticsTreatment optionsClindamycinClinical evidenceAcne vulgarisClinical basisProtein synthesis inhibitionDermatological indicationsAmeliorate inflammationAntibiotic resistanceDermatology practiceBacterial ribosomeDermatological diseasesClass antibioticsLesion formation
1973
Discriminatory Ribosome Rebinding of Isolated Regions of Protein Synthesis Initiation from the Ribonucleic Acid of Bacteriophage R17
Steitz J. Discriminatory Ribosome Rebinding of Isolated Regions of Protein Synthesis Initiation from the Ribonucleic Acid of Bacteriophage R17. Proceedings Of The National Academy Of Sciences Of The United States Of America 1973, 70: 2605-2609. PMID: 4582190, PMCID: PMC427065, DOI: 10.1073/pnas.70.9.2605.Peer-Reviewed Original ResearchConceptsR17 RNARibosome-binding siteProtein synthesis initiationEscherichia coli ribosomesPolypeptide chain initiationCoat protein regionRibosome bindingBacterial ribosomeRNA moleculesInitiator regionRibosome protectionSynthesis initiationMRNA moleculesInitiator codonColi ribosomesRibosomesNative RNABacteriophage R17Bacillus stearothermophilusRNAMessenger RNARibonucleic acidR17Replicase regionFragments
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply